Publication: Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin
Issued Date
2009-10-01
Resource Type
ISSN
10986596
00664804
00664804
Other identifier(s)
2-s2.0-70349313476
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antimicrobial Agents and Chemotherapy. Vol.53, No.10 (2009), 4545-4548
Suggested Citation
Weerawat Manosuthi, Somnuek Sungkanuparph, Preecha Tantanathip, Wiroj Mankatitham, Aroon Lueangniyomkul, Supeda Thongyen, Boonchuay Eampokarap, Sumonmal Uttayamakul, Pawita Suwanvattana, Samroui Kaewsaard, Kiat Ruxrungtham Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin. Antimicrobial Agents and Chemotherapy. Vol.53, No.10 (2009), 4545-4548. doi:10.1128/AAC.00492-09 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/27919
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin
Abstract
Seventy-one human immunodeficiency virus-infected patients with tuberculosis who were receiving a rifampin (rifampicin)-containing regimen were initiated on treatment with efavirenz at 600 mg/day plus stavudine-lamivudine. Fasting efavirenz concentrations at 12 h after dosing (C12) were monitored. The mean ± standard deviation efavirenz C12 at weeks 6 and 12 and after rifampin discontinuation were 4.5 ± 4.3, 3.8 ± 3.5, and 3.5 ± 2.7 mg/liter, respectively. High body weight was associated with a low efavirenz C12 at weeks 6 and 12 (P = 0.003, r = -0.255). The efavirenz C12 regression prediction line at 1 mg/liter intercepted a mean body weight of 57.5 kg. Copyright © 2009, American Society for Microbiology. All Rights Reserved.